Axonics, Inc.

NasdaqGS:AXNX Stock Report

Market Cap: US$3.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Axonics Management

Management criteria checks 3/4

Axonics' CEO is Ray Cohen, appointed in Oct 2013, has a tenure of 11.08 years. total yearly compensation is $7.37M, comprised of 10.9% salary and 89.1% bonuses, including company stock and options. directly owns 0.57% of the company’s shares, worth $20.62M. The average tenure of the management team and the board of directors is 7 years and 5.6 years respectively.

Key information

Ray Cohen

Chief executive officer

US$7.4m

Total compensation

CEO salary percentage10.9%
CEO tenure11.1yrs
CEO ownership0.6%
Management average tenure7yrs
Board average tenure5.6yrs

Recent management updates

Recent updates

Axonics' Market Growth Strengthens Boston Scientific's Future

Nov 05

A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Jul 14
A Look At The Fair Value Of Axonics, Inc. (NASDAQ:AXNX)

Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Jun 20
Axonics, Inc.'s (NASDAQ:AXNX) Earnings Haven't Escaped The Attention Of Investors

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Mar 27
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 21% Discount?

Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Feb 28
Here's Why We're Not At All Concerned With Axonics' (NASDAQ:AXNX) Cash Burn Situation

Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Nov 28
Is Axonics, Inc. (NASDAQ:AXNX) Trading At A 32% Discount?

Axonics stock falls 5.6% after Needham downgrades rating

Oct 10

Axonics Stock Is A Buy Amid Current Capex Cycle

Sep 07

Axonics prices stock offering of 1.75M shares

Aug 03

Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Aug 02
Companies Like Axonics (NASDAQ:AXNX) Can Afford To Invest In Growth

Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities

May 30

Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

Apr 19
Axonics (NASDAQ:AXNX) Is In A Strong Position To Grow Its Business

CEO Compensation Analysis

How has Ray Cohen's remuneration changed compared to Axonics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$6m

Jun 30 2024n/an/a

-US$2m

Mar 31 2024n/an/a

-US$16m

Dec 31 2023US$7mUS$800k

-US$6m

Sep 30 2023n/an/a

-US$12m

Jun 30 2023n/an/a

-US$32m

Mar 31 2023n/an/a

-US$46m

Dec 31 2022US$5mUS$750k

-US$60m

Sep 30 2022n/an/a

-US$76m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$80m

Dec 31 2021US$6mUS$625k

-US$80m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$68m

Mar 31 2021n/an/a

-US$63m

Dec 31 2020US$1mUS$527k

-US$55m

Sep 30 2020n/an/a

-US$66m

Jun 30 2020n/an/a

-US$82m

Mar 31 2020n/an/a

-US$81m

Dec 31 2019US$6mUS$500k

-US$80m

Sep 30 2019n/an/a

-US$67m

Jun 30 2019n/an/a

-US$49m

Mar 31 2019n/an/a

-US$39m

Dec 31 2018US$1mUS$430k

-US$32m

Sep 30 2018n/an/a

-US$28m

Jun 30 2018n/an/a

-US$25m

Mar 31 2018n/an/a

-US$20m

Dec 31 2017US$605kUS$430k

-US$18m

Compensation vs Market: Ray's total compensation ($USD7.37M) is about average for companies of similar size in the US market ($USD6.53M).

Compensation vs Earnings: Ray's compensation has increased whilst the company is unprofitable.

CEO

Ray Cohen (65 yo)

11.1yrs

Tenure

US$7,369,375

Compensation

Mr. Raymond W. Cohen, also known as Ray, is Independent Director of Kestra Medical Technologies, Inc. from July 2024. Mr. Cohen is Venture Advisor of Andera Partners. He focuses on Life Sciences.He works...

Leadership Team

NamePositionTenureCompensationOwnership
Raymond Cohen
CEO & Director11.1yrsUS$7.37m0.57%
$ 20.6m
Kari Keese
Chief Financial Officer1.1yrsUS$3.76m0.079%
$ 2.8m
Rinda Sama
Chief Operating Officer6.3yrsUS$3.04m0.17%
$ 6.0m
John Woock
Executive VP6.4yrsUS$3.26m0.15%
$ 5.5m
Alfred Ford
Chief Commercial Officer7yrsUS$2.94m0.085%
$ 3.1m
Guangqiang Jiang
Chief Technology Officer11.1yrsno datano data
Neil Bhalodkar
Vice President of Investor Relationsno datano datano data
Aaron Pettit
General Counsel & Chief Compliance Officerno datano datano data
Michael Williamson
Senior VPno datano datano data
Karen Noblett
Chief Medical Officer7.1yrsUS$651.40k0.067%
$ 2.4m
Prabodh Mathur
Chief Product Development Officer10.5yrsno datano data

7.0yrs

Average Tenure

52yo

Average Age

Experienced Management: AXNX's management team is seasoned and experienced (7 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Raymond Cohen
CEO & Director11.1yrsUS$7.37m0.57%
$ 20.6m
Michael Carrel
Independent Chairman5.8yrsUS$250.00k0.035%
$ 1.3m
Nancy Snyderman
Independent Director5.6yrsUS$222.50k0.039%
$ 1.4m
David Demski
Independent Director3.8yrsUS$210.00k0.019%
$ 672.2k
Robert McNamara
Independent Director6yrsUS$227.50k0.029%
$ 1.0m
Jane Kiernan
Independent Director5.6yrsUS$225.00k0.039%
$ 1.4m
Esteban Lopez
Independent Director3.3yrsUS$215.00k0.013%
$ 464.8k

5.6yrs

Average Tenure

65yo

Average Age

Experienced Board: AXNX's board of directors are considered experienced (5.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/11/14 12:44
End of Day Share Price 2024/11/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Axonics, Inc. is covered by 9 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Travis SteedBarclays
Travis SteedBofA Global Research
Christopher PasqualeGuggenheim Securities, LLC